How to buy NovaBay Pharmaceuticals stock - 04 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NovaBay Pharmaceuticals stock

Own NovaBay Pharmaceuticals stock in just a few minutes.


Fact checked

NovaBay Pharmaceuticals, Inc is a biotechnology business based in the US. NovaBay Pharmaceuticals shares (NBY) are listed on the NYSE MKT and all prices are listed in US Dollars. NovaBay Pharmaceuticals employs 26 staff and has a trailing 12-month revenue of around USD$9.8 million.

How to buy shares in NovaBay Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for NovaBay Pharmaceuticals. Find the stock by name or ticker symbol: NBY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until NovaBay Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of NovaBay Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of NovaBay Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

NovaBay Pharmaceuticals share price

Use our graph to track the performance of NBY stocks over time.

NovaBay Pharmaceuticals shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$0.24 - USD$1.64
50-day moving average USD$1.0882
200-day moving average USD$0.8135
Wall St. target priceUSD$2.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.584

Buy NovaBay Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NovaBay Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NovaBay Pharmaceuticals financials

Revenue TTM USD$9.8 million
Gross profit TTM USD$4.9 million
Return on assets TTM -26.72%
Return on equity TTM -137.69%
Profit margin -122.27%
Book value $0.332
Market capitalisation USD$43.5 million

TTM: trailing 12 months

Shorting NovaBay Pharmaceuticals shares

There are currently 861,421 NovaBay Pharmaceuticals shares held short by investors – that's known as NovaBay Pharmaceuticals's "short interest". This figure is 17.3% down from 1.0 million last month.

There are a few different ways that this level of interest in shorting NovaBay Pharmaceuticals shares can be evaluated.

NovaBay Pharmaceuticals's "short interest ratio" (SIR)

NovaBay Pharmaceuticals's "short interest ratio" (SIR) is the quantity of NovaBay Pharmaceuticals shares currently shorted divided by the average quantity of NovaBay Pharmaceuticals shares traded daily (recently around 5.7 million). NovaBay Pharmaceuticals's SIR currently stands at 0.15. In other words for every 100,000 NovaBay Pharmaceuticals shares traded daily on the market, roughly 150 shares are currently held short.

However NovaBay Pharmaceuticals's short interest can also be evaluated against the total number of NovaBay Pharmaceuticals shares, or, against the total number of tradable NovaBay Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NovaBay Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 NovaBay Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0276% of the tradable shares (for every 100,000 tradable NovaBay Pharmaceuticals shares, roughly 28 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NovaBay Pharmaceuticals.

Find out more about how you can short NovaBay Pharmaceuticals stock.

NovaBay Pharmaceuticals share dividends

We're not expecting NovaBay Pharmaceuticals to pay a dividend over the next 12 months.

Have NovaBay Pharmaceuticals's shares ever split?

NovaBay Pharmaceuticals's shares were split on a 1:25 basis on 21 December 2015. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NovaBay Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for NovaBay Pharmaceuticals shares which in turn could have impacted NovaBay Pharmaceuticals's share price.

NovaBay Pharmaceuticals share price volatility

Over the last 12 months, NovaBay Pharmaceuticals's shares have ranged in value from as little as $0.24 up to $1.64. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while NovaBay Pharmaceuticals's is 3.6996. This would suggest that NovaBay Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

NovaBay Pharmaceuticals overview

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site